BioSense Global and Rexahn Announce Collaboration and License Agreement for RX-3117 in Greater China
| Press Release
BioSense Global and Rexahn collaborate and sign License Agreement to advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China.
